Impact of extended-spectrum [beta]-lactamase-producing organisms on clinical and economic outcomes in patients with urinary tract infection

OBJECTIVE To compare clinical and economic outcomes between patients with urinary tract infection (UTI) due to extended-spectrum [beta]-lactamase-producing Escherichia coli and Klebsiella species (ESBL-EK) versus patients with non-ESBL-EK UTI. PATIENTS AND METHODS Eighty-four (3.6%) of 2345 patients admitted between September 1, 2011 and August 31, 2012 with UTI were positive for ESBL-EK. Fifty-five ESBL-EK UTI (cases) and matched controls (non-ESBL-EK UTI) were included in the analysis. Clinical and economic outcomes were compared between cases and controls for statistical significance. RESULTS Cases were more likely to have diabetes mellitus, a history of recurrent UTIs, recently received antibiotics, recently been hospitalized, and had previous isolation of an ESBL-producing organism compared with controls. Failure of initial antibiotic regimen (62% vs 6%; P